Free Trial
NASDAQ:SGRY

Surgery Partners (SGRY) Stock Price, News & Analysis

Surgery Partners logo
$22.13 -0.38 (-1.69%)
(As of 09:48 AM ET)

About Surgery Partners Stock (NASDAQ:SGRY)

Key Stats

Today's Range
$22.13
$22.58
50-Day Range
$21.83
$33.13
52-Week Range
$21.36
$36.92
Volume
16,255 shs
Average Volume
966,483 shs
Market Capitalization
$2.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.71
Consensus Rating
Moderate Buy

Company Overview

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Surgery Partners Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
62nd Percentile Overall Score

SGRY MarketRank™: 

Surgery Partners scored higher than 62% of companies evaluated by MarketBeat, and ranked 433rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Surgery Partners has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Surgery Partners has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Surgery Partners' stock forecast and price target.
  • Earnings Growth

    Earnings for Surgery Partners are expected to grow by 33.73% in the coming year, from $0.83 to $1.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Surgery Partners is -46.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Surgery Partners is -46.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Surgery Partners has a PEG Ratio of 16.71. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Surgery Partners has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Surgery Partners' valuation and earnings.
  • Percentage of Shares Shorted

    14.30% of the float of Surgery Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Surgery Partners has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Surgery Partners has recently increased by 0.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Surgery Partners does not currently pay a dividend.

  • Dividend Growth

    Surgery Partners does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.30% of the float of Surgery Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Surgery Partners has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Surgery Partners has recently increased by 0.40%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Surgery Partners has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Surgery Partners this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for SGRY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive SGRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgery Partners and its competitors with MarketBeat's FREE daily newsletter.

SGRY Stock News Headlines

Surgery Partners (NASDAQ:SGRY) Given "Outperform" Rating at Macquarie
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
Surgery Partners price target lowered to $31 from $32 at Barclays
Surgery Partners Reports Q3 Revenue Growth Amid Challenges
See More Headlines

SGRY Stock Analysis - Frequently Asked Questions

Surgery Partners' stock was trading at $31.99 at the start of the year. Since then, SGRY stock has decreased by 29.6% and is now trading at $22.51.
View the best growth stocks for 2024 here
.

Surgery Partners, Inc. (NASDAQ:SGRY) released its quarterly earnings results on Tuesday, November, 12th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by $0.06. The firm's revenue for the quarter was up 14.3% on a year-over-year basis.

Surgery Partners' top institutional shareholders include FMR LLC (14.40%), Wellington Management Group LLP (7.75%), Janus Henderson Group PLC (4.32%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Andrew T Kaplan, Jason Eric Evans, Jennifer Baldock, Wayne S Deveydt, David T Doherty, Bradley R Owens, Brent Turner, Harrison R Bane, Laura L Brocklehurst, George Goodwin, Marissa Brittenham, Danielle Burkhalter, Teresa Deluca and Anthony Taparo.
View institutional ownership trends
.

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Surgery Partners investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/24/2025

Industry, Sector and Symbol

Sector
Medical
Industry
General medical & surgical hospitals
Sub-Industry
Healthcare
Current Symbol
NASDAQ:SGRY
Employees
13,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.71
High Stock Price Target
$50.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+72.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-11,900,000.00
Pretax Margin
4.21%

Debt

Sales & Book Value

Annual Sales
$2.74 billion
Cash Flow
$1.76 per share
Book Value
$23.99 per share

Miscellaneous

Free Float
124,190,000
Market Cap
$2.86 billion
Optionable
Optionable
Beta
2.76

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SGRY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners